265 related articles for article (PubMed ID: 25741864)
1. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy.
Berrier KL; Kazi ZB; Prater SN; Bali DS; Goldstein J; Stefanescu MC; Rehder CW; Botha EG; Ellaway C; Bhattacharya K; Tylki-Szymanska A; Karabul N; Rosenberg AS; Kishnani PS
Genet Med; 2015 Nov; 17(11):912-8. PubMed ID: 25741864
[TBL] [Abstract][Full Text] [Related]
2. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy.
Desai AK; Kazi ZB; Bali DS; Kishnani PS
Mol Genet Metab Rep; 2019 Sep; 20():100475. PubMed ID: 31193175
[TBL] [Abstract][Full Text] [Related]
3. An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.
Kazi ZB; Desai AK; Troxler RB; Kronn D; Packman S; Sabbadini M; Rizzo WB; Scherer K; Abdul-Rahman O; Tanpaiboon P; Nampoothiri S; Gupta N; Feigenbaum A; Niyazov DM; Sherry L; Segel R; McVie-Wylie A; Sung C; Joseph AM; Richards S; Kishnani PS
Genet Med; 2019 Apr; 21(4):887-895. PubMed ID: 30214072
[TBL] [Abstract][Full Text] [Related]
4. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.
Banugaria SG; Prater SN; Patel TT; Dearmey SM; Milleson C; Sheets KB; Bali DS; Rehder CW; Raiman JA; Wang RA; Labarthe F; Charrow J; Harmatz P; Chakraborty P; Rosenberg AS; Kishnani PS
PLoS One; 2013; 8(6):e67052. PubMed ID: 23825616
[TBL] [Abstract][Full Text] [Related]
5. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
Rairikar M; Kazi ZB; Desai A; Walters C; Rosenberg A; Kishnani PS
Mol Genet Metab; 2017 Sep; 122(1-2):76-79. PubMed ID: 28648664
[TBL] [Abstract][Full Text] [Related]
6. Atypical immunologic response in a patient with CRIM-negative Pompe disease.
Abbott MA; Prater SN; Banugaria SG; Richards SM; Young SP; Rosenberg AS; Kishnani PS
Mol Genet Metab; 2011 Dec; 104(4):583-6. PubMed ID: 21889385
[TBL] [Abstract][Full Text] [Related]
7. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
Front Immunol; 2020; 11():1727. PubMed ID: 32849613
[TBL] [Abstract][Full Text] [Related]
8. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.
Bali DS; Goldstein JL; Banugaria S; Dai J; Mackey J; Rehder C; Kishnani PS
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):40-9. PubMed ID: 22252923
[TBL] [Abstract][Full Text] [Related]
9. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
[TBL] [Abstract][Full Text] [Related]
10. A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.
Gupta P; Shayota BJ; Desai AK; Kiblawi F; Myridakis D; Messina J; Tah P; Tambini-King L; Kishnani PS
Front Immunol; 2020; 11():1929. PubMed ID: 33013846
[TBL] [Abstract][Full Text] [Related]
11. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.
van Gelder CM; Hoogeveen-Westerveld M; Kroos MA; Plug I; van der Ploeg AT; Reuser AJ
J Inherit Metab Dis; 2015 Mar; 38(2):305-14. PubMed ID: 24715333
[TBL] [Abstract][Full Text] [Related]
12. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
Wang Z; Okamoto P; Keutzer J
Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
[TBL] [Abstract][Full Text] [Related]
13. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction.
Li C; Desai AK; Gupta P; Dempsey K; Bhambhani V; Hopkin RJ; Ficicioglu C; Tanpaiboon P; Craigen WJ; Rosenberg AS; Kishnani PS
Genet Med; 2021 May; 23(5):845-855. PubMed ID: 33495531
[TBL] [Abstract][Full Text] [Related]
14. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
[TBL] [Abstract][Full Text] [Related]
15. CRIM-negative infantile Pompe disease: 42-month treatment outcome.
Rohrbach M; Klein A; Köhli-Wiesner A; Veraguth D; Scheer I; Balmer C; Lauener R; Baumgartner MR
J Inherit Metab Dis; 2010 Dec; 33(6):751-7. PubMed ID: 20882352
[TBL] [Abstract][Full Text] [Related]
16. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
[TBL] [Abstract][Full Text] [Related]
17. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.
Elder ME; Nayak S; Collins SW; Lawson LA; Kelley JS; Herzog RW; Modica RF; Lew J; Lawrence RM; Byrne BJ
J Pediatr; 2013 Sep; 163(3):847-54.e1. PubMed ID: 23601496
[TBL] [Abstract][Full Text] [Related]
18. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
Kishnani PS; Goldenberg PC; DeArmey SL; Heller J; Benjamin D; Young S; Bali D; Smith SA; Li JS; Mandel H; Koeberl D; Rosenberg A; Chen YT
Mol Genet Metab; 2010 Jan; 99(1):26-33. PubMed ID: 19775921
[TBL] [Abstract][Full Text] [Related]
19. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent.
Nayak S; Doerfler PA; Porvasnik SL; Cloutier DD; Khanna R; Valenzano KJ; Herzog RW; Byrne BJ
PLoS One; 2014; 9(6):e98336. PubMed ID: 24897114
[TBL] [Abstract][Full Text] [Related]
20. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation.
Desai AK; Shrivastava G; Grant CL; Wang RY; Burt TD; Kishnani PS
Front Immunol; 2024; 15():1360369. PubMed ID: 38524130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]